Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Prexigebersen by Bio-Path for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
Prexigebersen is under clinical development by Bio-Path and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to GlobalData,...
Prexigebersen by Bio-Path for Refractory Acute Myeloid Leukemia: Likelihood of Approval
Prexigebersen is under clinical development by Bio-Path and currently in Phase II for Refractory Acute Myeloid Leukemia. According to GlobalData,...
Prexigebersen by Bio-Path for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
Prexigebersen is under clinical development by Bio-Path and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)....